Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 8/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.57 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.57 |
| ▸ | ITGAL | P20701 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 3/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017027 | 0.92 | NMBR (0.61) | NMBRALOX15ACEITGB2ICAM1 | |
| SCHEMBL8785114 | 0.89 | KCNA5 (0.63) | NMBRALOX15ACEITGB2ICAM1 | |
| SCHEMBL3820631 | 0.89 | KCNA5 (0.63) | NMBRALOX15ACEITGB2ICAM1 | |
| SCHEMBL4612012 | 0.89 | KCNA5 (0.63) | NMBRALOX15ACEITGB2ICAM1 | |
| SCHEMBL12017029 | 0.88 | NMBR (0.64) | NMBRALOX15ACEITGB2ICAM1 | |
| SCHEMBL11370918 | 0.87 | ALOX15 (0.67) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL11370921 | 0.87 | ALOX15 (0.67) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL29062752 | 0.86 | NMBR (0.74) | NMBRALOX15ACE | |
| SCHEMBL29062748 | 0.86 | NMBR (0.74) | NMBRALOX15ACE | |
| Hydrochloric Acid SCHEMBL27463103 | 0.86 | ALOX15 (0.66) | ALOX15ACEITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219538-A1 | STABILIZED PROTEIN FORMULATIONS AND USE THEREOF | THERAPEOMIC AG (CH) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219538-A1 | STABILIZED PROTEIN FORMULATIONS AND USE THEREOF | TTR, ALB, CRYZ | NMBR 2950/4885ALOX15 4039/4885ACE 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.